Medical technology company Cyberonics has implanted 100,000th patient using its Vagus Nerve Stimulation (VNS) therapy system.
Using implanted medical device, the CE-marked VNS therapy system delivers pulsed electrical signals to the vagus nerve for treating refractory epilepsy, in addition to treatment-resistant depression.
Published data from New York University showed that more than 60% of people with refractory epilepsy treated with adjunctive VNS therapy experience 50% or greater reduction in seizures.
In addition, published data from Emory University has shown that treating refractory epilepsy patients with VNS therapy is associated with significant reductions in resource utilization (ER visits, hospitalizations, and inpatient days) and epilepsy related clinical events, as well as a net cost savings after 1.5 years.
Cyberonics president and chief executive officer Dan Moore said, "We look forward to expanding access to VNS Therapy and innovating new therapeutic options for patients around the world."
